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Introduction
Nicotinic acid (niacin) is a lipid-altering therapy used
since the 1950s (1) that effectively raises high-density
lipoprotein cholesterol (HDL-C) levels. Niacin also
reduces triglyceride (TG), and particularly at higher
doses, signiﬁcantly lowers low-density lipoprotein
cholesterol levels (2,3). The clinical trial data support
niacin as a therapeutic agent that reduces the risk of
atherosclerotic coronary heart disease (CHD) events
and reduces atherosclerotic progression in patients
with CHD and⁄or other cardiovascular risk factors (4–
18). Although the favourable lipid effects of niacin
have been known for decades, it is less recognised that
niacin may also favourably lower blood pressure (BP).
The major adverse experience limiting the more
widespread use of niacin is cutaneous vasodilation
resulting in ﬂushing (19–21). Other vasoactive prop-
erties of niacin include possible improvements in
vascular headaches (22). The package insert for cer-
tain niacin prescription formulations describe rare
cases of acute syncope, hypotension, and postural
hypotension, especially when co-administered with
ganglionic-blocking and vasoactive medications
(23,24). However, there is a paucity of peer-reviewed
published literature regarding these acute effects and
potential drug interactions, and published data
regarding niacin’s chronic BP effects are limited.
Methods
The literature supporting this review was derived
from an English-language search of PubMed using
the title words ‘niacin’ or ‘nicotinic acid’ along with
various Medical Subject Heading (MeSH) terms (in
various combinations), including ‘adult’, ‘blood’,
‘blood pressure’, ‘blood pressure monitoring, ambula-
tory’, ‘blood supply’, ‘cardiac output’, ‘catecholam-
ines’, ‘epinephrine’, ‘heart rate’, ‘hemodynamic
processes’, ‘human’, ‘hypertension’, ‘hypotension’,
‘norepinephrine’, ‘randomized controlled trials’,
‘stroke volume’, ‘vascular resistance’ and ‘vasodilator
agents’. Additional references were obtained from
treatment guidelines and other English-language pub-
lications involving major clinical outcome reviews
and angiographic or ultrasonographic studies that
included reported mean BP at baseline and at end-
point. Case reports and case studies were excluded.
SUMMARY
Nicotinic acid (niacin) is a well-established treatment for dyslipidaemia – an impor-
tant cardiovascular disease (CVD) risk factor. However, niacin may also reduce
blood pressure (BP), which is another important CVD risk factor. This review exam-
ines the limited publicly available data on niacin’s BP effects. Acute administration
of immediate-release niacin may lower BP because of niacin’s acute vasodilatory
effects. Although not always supported by clinical trial data, the package insert of
a prescription, extended-release niacin describes niacin-induced acute hypotension.
From a chronic standpoint, larger studies, such as the Coronary Drug Project, sug-
gest that niacin may lower BP when administered over a longer period of time.
Post hoc analyses of some of the more recent niacin clinical trials also support a
more chronic, dose-dependent, BP-lowering effect of niacin. Because laropiprant [a
prostaglandin D2 (PGD2) type 1 (DP1) receptor antagonist] does not attenuate nia-
cin’s BP-lowering effects, it is unlikely that any chronic lowering of BP by niacin is
due to dilation of dermal vessels through activation of the DP1 receptor by PGD2.
Further research is warranted to evaluate the extent and mechanisms of niacin’s
effects on BP.
Review Criteria
The information collected for this review included a
literature search using key terms. The trials selected
and described in this review were those that
contained data describing nicotinic acid’s acute and
chronic effects upon blood pressure.
Message for the Clinic
Nicotinic acid is a well-known lipid-altering drug.
The improved cardiovascular outcomes with
nicotinic acid therapy are thought to be related to
its favourable lipid effects. However, less known is
that nicotinic acid may also lower blood pressure,
particularly at higher doses administered over a
longer period of time. It is possible that some of
nicotinic acid’s cardiovascular outcome beneﬁts may
be related to an improvement in high blood
pressure, which is a major cardiovascular disease
risk factor.
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Acute effects of niacin on blood pressure
and related haemodynamic parameters
Two illustrative published studies speciﬁcally evalu-
ated and reported the short-term effects of niacin on
BP (25,26). In one parallel-group study, BP and
other haemodynamic parameters [e.g. waveform data
on stroke volume (SV), cardiac output (CO) and
systemic vascular resistance (SVR)] were measured at
0, 15 and 30 min during a 30-min baseline period,
followed by niacin infusion at 2.8 mg⁄min for up to
60 min. After niacin infusion, this study evaluated
similar BP and haemodynamic measurements at 30,
45 and 60 min in 11 normotensive and 10 hyperten-
sive subjects (stage 1 hypertension) (25). Intravenous
niacin infusion (2.8 mg⁄min; 0.04 mg⁄kg⁄min)
had no signiﬁcant effects on BP in normotensive
individuals (n = 11; average seated BP £ 130⁄80
mmHg) (25). CO (determined by pulse waveform
analysis) was unaffected by niacin infusion at 30 and
60 min in these subjects; however, mean heart rate
(HR) increased by 12% to 13%, from 59 beats⁄min-
ute (bpm) at baseline to 66 to 67 bpm at 30 to
60 min (p < 0.01). This chronotropic effect of niacin
in normotensives was associated with signiﬁcant
acute declines in (i) SVR 60 min after niacin infu-
sion, (ii) SV at 30 min, (iii) overall vascular compli-
ance [expressed as the SV⁄pulse pressure (PP) ratio]
at 30 and 60 min and (iv) the mean large-artery elas-
ticity index at 30 and 60 min (Table 1) (25). Small-
artery elasticity did not undergo signiﬁcant change.
In contrast, this same study suggested that acute
niacin administration may lower BP in patients with
hypertension. Those with hypertension experienced
signiﬁcant decreases in systolic BP (SBP), diastolic
BP (DBP), mean arterial pressure (MAP), PP, SVR
and SV from baseline at up to 60 min after the onset
of niacin infusion (Table 1) (25). Signiﬁcant
decreases from baseline were observed in (i) mean
SBP by a maximum of 7 mmHg (5%), (ii) DBP by a
maximum of 4 mmHg (4%), (iii) MAP by a maxi-
mum of 6 mmHg (6%), (iv) PP by a maximum of
3 mmHg (6%), (v) SVR by a maximum of
84 dynes⁄s⁄cm
5 (6%) at 60 min after an initial
increase and (vi) SV by a maximum of 9 ml⁄beat
(10%; each p £ 0.05 vs. baseline). HR increased sig-
niﬁcantly in patients with hypertension, by a similar
proportion to the effect observed in normotensives
[maximum = 10 bpm (11%); p £ 0.01 vs. baseline],
although patients with hypertension had a signiﬁ-
cantly higher HR at baseline (71 vs. 59 bpm;
p £ 0.01). Unlike their normotensive counterparts,
patients with hypertension did not experience signiﬁ-
cant acute declines in overall vascular compliance or
the large-artery elasticity index (25).
One proposed mechanism for niacin’s divergent
effects on BP in normotensives compared with those
with hypertension is differential effects upon large-
artery compliance. In normotensive patients, chrono-
tropic responses to niacin infusion were similar to
the responses in those with hypertension, but these
acute increases in HR did not affect CO in normo-
tensives, possibly because of a countervailing signiﬁ-
cant decrease in SV. The ﬁnding of stable BP despite
a signiﬁcant acute decrease in SVR in normotensives
may suggest that peripheral vasodilation triggers
counter-regulatory mechanisms, potentially with
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Table 1 Acute haemodynamic effects of niacin infusion in normotensive and hypertensive subjects
Haemodynamic
parameter (mean ± SD)
Normotensives (n = 11) Hypertensives (n = 10)
Baseline 30 min 60 min Baseline 30 min 60 min
Systolic BP, mmHg 109 ± 3 109 ± 2 108 ± 2 136 ± 4 130 ± 3§ 129 ± 3§
Diastolic BP, mmHg 65 ± 2 62 ± 2 63 ± 2 89 ± 2 84 ± 3*§ 85 ± 3*§
Mean BP, mmHg 79 ± 2 78 ± 2 78 ± 2 105 ± 2 99 ± 2§ 100 ± 3§
Pulse pressure, mmHg 44 ± 2 46 ± 2 45 ± 2 47 ± 2 46 ± 2 44 ± 2*
Heart rate, beats⁄min 59 ± 2 67 ± 3 66 ± 3 71 ± 3§ 81 ± 4 79 ± 4
Stroke volume, ml⁄beat 91 ± 3 85 ± 5* 86 ± 4 88 ± 5 79 ± 6* 80 ± 6*
Cardiac output, l⁄min 5.4 ± 0.2 5.5 ± 0.2 5.5 ± 0.15 6.0 ± 0.2 6.0 ± 3 5.9 ± 0.3
Systemic vascular resistance, dynes⁄s⁄cm
5 1215 ± 44 1156 ± 45 1145 ± 41* 1492 ± 93 1515 ± 182 1408 ± 99*
SV⁄PP (overall compliance), ml⁄mmHg 2.12 ± 0.09 1.84 ± 0.11 1.93 ± 0.09* 1.91 ± 0.14 1.76 ± 0.19 1.89 ± 0.16
C1 (large-artery elasticity index) 15.8 ± 1.0 13.9 ± 1.0* 14.2 ± 1.0* 11.9 ± 1.0§ 11.3 ± 1.4 11.4 ± 1.2
C2 (small-artery elasticity index) 7.5 ± 1.1 7.1 ± 0.5 6.7 ± 1.1 6.5 ± 1.1 5.4 ± 1.1 5.6 ± 1.0
*p £ 0.05, p £ 0.01 for comparison with baseline; p £ 0.05, §p £ 0.01 for comparison between hypertensive and normotensive
subjects. Reproduced with permission from Gadegbeku et al. (25). BP, blood pressure; SV, stroke volume; PP, pulse pressure.
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cant acute depressor effects of niacin infusion in
patients with hypertension may reﬂect a reduced
ability to modulate large-artery compliance. Those
with hypertension are known to have decreased vas-
cular compliance and may also have vascular stiffness
that is less responsive to changes in counter-regula-
tory vasoconstrictor hormones (27). The fact that the
chronotropic effects of niacin infusion were similar
in patients with or without hypertension, but were
insufﬁcient to maintain BP in those with hyperten-
sion, may also suggest impaired baroreceptor
responses in these patients (28). Another mechanism,
albeit less likely, for the signiﬁcant acute depressor
effects of niacin in patients with hypertension is an
increased prostacyclin response to niacin in the vas-
culature of these patients compared with their nor-
motensive counterparts (25).
Given that niacin presumably has similar meta-
bolic effects in those with high BP compared with
those with normal BP, then niacin-related metabolic
effects would not be a plausible explanation for BP
differences between hypertensive versus non-hyper-
tensive groups (25,29). However, niacin does affect
metabolic parameters often thought to affect BP,
such as circulating free fatty acids (FFAs). After acute
oral administration of 500 mg of niacin in man, arte-
rial FFA levels decrease within minutes. After about
2 h, FFAs undergo a ‘rebound’ elevation (30). In
longer-term trials of chronic oral niacin administra-
tion, this ‘rebound’ (21,31–33) has been described to
last as long as ‡ 9 h, resulting in increased circulating
FFAs (21,31–34). Increased FFAs have been hypo-
thesised to contribute to insulin resistance (26,34),
which, in turn, may contribute to high BP (35).
The observation that niacin acutely decreases FFA
levels for a few hours might conceivably be consistent
with an acute decrease in BP. However, it is unclear if
niacin administration increases or decreases total daily
FFA release and circulatory exposure. Furthermore,
studies suggest that extended-release niacin may have
less potential for FFA rebound (vs. immediate-release
formulations), especially after several months of use
(36). In the previously described study regarding intra-
venous niacin’s effects upon BP, the haemodynamic
responses to niacin in hypertensive vs. normotensive
subjects were not ascribed to between-group differ-
ences in effects of niacin on FFAs or TG (25). Because
the relationship of niacin’s effects on FFAs and BP is
uncertain, it seems unlikely that the short-term, acute
reduction in FFA would account for acute BP lower-
ing. From a more chronic standpoint, if a rebound
increased in FFA and increased in insulin resistance
were anticipated to have any BP effect, then it would
be expected to raise, not lower, chronic BP (35).
A second illustrative study evaluating the potential
relationship between niacin’s effects on FFAs, insulin
sensitivity, and BP was a prospective, randomised,
double-blind, placebo-controlled crossover study in
seven healthy volunteers (26). The active treatment
was immediate-release niacin orally administered as
one 250-mg capsule twice daily for the ﬁrst week,
followed by two 250-mg capsules twice daily for the
second week. Using the hyperinsulinaemic–euglycae-
mic clamp method, the investigators found that nia-
cin reduced insulin sensitivity compared with
placebo and signiﬁcantly decreased the rate of glu-
cose infusion needed to maintain euglycaemia (26.2
vs. 31.5 lmol⁄kg⁄min; p = 0.002). This was attribut-
able to a decline in non-oxidative glucose disposal
associated with niacin treatment. Interestingly, with
the twice daily dosing regimen, fasting glucose, insu-
lin, FFAs, energy intake and substrate oxidation were
unchanged compared with placebo. However, despite
the increase in insulin resistance, niacin administra-
tion did not signiﬁcantly affect SBP or DBP com-
pared with placebo (Table 2) (26).
Thus the extent to which, and the mechanisms by
which short-term niacin administration affects BP
remain unclear. However, what is clear is that niacin
administration often causes ﬂushing because of
marked vasodilation, and up to a 100% increase in
cutaneous perfusion and up to a 200% increase in
skeletal-muscle blood perfusion (37). Given the sig-
niﬁcant surface area of skin and the degree of
increased cutaneous blood perfusion that can occur
with niacin, one might speculate that when niacin
does acutely lower BP, in the absence of cardiac
dysrhythmias, this may, in part, be due to shunting
Table 2 Acute metabolic and haemodynamic effects of
niacin
Parameter (mean ± SEM) Placebo Niacin
Glucose infusion rate,
lmol⁄kg FFM⁄min
41.5 ± 5.8 34.2 ± 6.8*
Non-oxidative glucose
disposal, mg⁄min
314 ± 73 218 ± 66*
Mean 24-h blood pressure
(BP), mmHg
82.1 ± 2.0 81.8 ± 3.3
24-h systolic BP, mmHg 112.6 ± 2.3 115.3 ± 4.4
24-h diastolic BP, mmHg 67.1 ± 2.0 65.1 ± 2.8
Forearm blood ﬂow,
ml⁄100 ml⁄min
4.3 ± 0.3 4.8 ± 0.4
Plasma nitrate, lmol⁄l 18.4 ± 2.4 17.0 ± 4.2
Urinary nitrate, lmol⁄l 686 ± 126 705 ± 194
Urinary prostaglandin E2, ng⁄24 h 287 ± 56 195 ± 42
FFM, fat-free mass. *p = 0.002. Reproduced with permission
from Kelly et al. (26).
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and end-point
Study Patients
Duration;
outcome measure
Daily dose of
regimen (n with
available BL and
EP data for BP)
Baseline
mean BP, mmHg
End-point
(or on-trial)
mean BP, mmHg Comparison
Niacin monotherapy
Coronary Drug
Project (39)
n = 8341 men with
previous MI
5–8.5 years; total
mortality (also
coronary events)
Niacin 3.0 g (n = 621) SBP = 129.7
DBP = 81.7
SBP = 131.7
DBP = 80.2
z = )1.40* vs. placebo
for SBP
z = )1.11* vs. placebo
for DBP
Placebo (n = 1607)
Placebo (n = 1606)
SBP = 129.1
DBP = 81.5
SBP = 132.3
DBP = 80.6
See above
Niacin-containing regimens
AFREGS,
Whitney et al.
(18)
n = 143 military
retirees ages
< 76 years with CHD
and low HDL-C
30 months (50 weeks
for BP); primary: %
change in global
angiographic stenosis;
secondary: composite
end-point (hosp. for
angina, MI, TIA and
stroke, death, and CV
procedures (also
angiographic
end-points)
Stepped care (n = 71):
gemﬁbrozil 1.2 g⁄day
Niacin 0.25–3.0 g⁄day
CME: 2–16 g⁄day
SBP = 139.0
DBP = 75.3
DSBP = )9.8%
DDBP = 6.8%
SBP p = 0.14 vs.
placebo
DBP p > 0.2 vs.
placebo
Placebo (n = 72) SBP = 138.9
DBP = 76.3
DSBP = )6.6%
DDBP = 4.3%
HATS, Brown
et al. (8)
n = 160 patients with
CHD and low HDL-C;
146 patients
completed treatment
3 years; arteriographic
evidence of Dcoronary
stenosis + ﬁrst CV
event (death, MI,
stroke,
revascularisation)
Niacin 0.5–4 g
(mean = 2.4 g) +
simvastatin 10–20 mg
(mean = 13 mg)
(n = 33)
SBP⁄DBP = 124⁄78 SBP⁄DBP = 125⁄77 ns vs. baseline
Niacin–simvastatin
(as above) +
antioxidants (800 IU
vitamin E, 1 g,
vitamin C; 25 mg,
b-carotene; 100 lg
selenium) (n = 40)
SBP⁄DBP = 130⁄81 SBP⁄DBP = 129⁄79 p < 0.05 vs. baseline
Placebo (n = 34) SBP⁄DBP = 125⁄80 SBP⁄DBP = 127⁄80 ns vs. baseline
CLAS,
Blankenhorn
et al. (6)
n = 78 non-smoking
men ages 40–
59 years with history
of CABG
Up to 4 years; common
carotid intima-media
thickening
Niacin: mean = 4.2 g
Colestipol:
mean = 30.1 g
(n = 24)
SBP = 122
DBP = 79
SBP = 118
DBP = 78
BL: p = 0.33 vs.
placebo (SBP)
p = 0.32 vs. placebo
(DBP)
EP: p = 0.86 vs.
placebo (SBP)
p = 0.83 vs. placebo
(DBP)
Placebo (n = 22) SBP = 118
DBP = 77
SBP = 119
DBP = 89
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vessels (and possibly skeletal muscle vessels). Clini-
cally, during whole-body heat stress, active vasodila-
tion is known to account for 85–95% of the overall
cutaneous vasodilator response, which may increase
cutaneous vascular conductance and contribute to
orthostasis (38). It is therefore plausible that vasodi-
latation might be responsible for the acute BP-lower-
ing effects of niacin in rare patients, although other
cardiovascular mechanisms (such as direct effects on
the heart and other vessels) cannot be excluded.
Effects of chronic niacin therapy on blood
pressure
Among studies of chronic niacin administration that
reported both baseline and on-treatment mean values
for SBP and DBP (or changes in BP), most described
BP changes from baseline to end-point (or between
niacin-treated and control groups) that were not
statistically signiﬁcant (Table 3) (6,8,13,18,39).
Although a substantial proportion of subjects in
these trials had a history of hypertension and⁄or
used antihypertensive medications (40–70%) (4,18),
these trials generally failed to report the use of anti-
hypertensive medications, changes in medication dur-
ing the study, or incident hypertension (or
hypotension) in patients receiving niacin or niacin-
containing regimens compared with control groups.
Thus, these trials are not optimal in assessing the
potential chronic BP-lowering effects of niacin.
In the original Coronary Drug Project (CDP)
report, niacin signiﬁcantly reduced the incidence
of deﬁnite, non-fatal myocardial infarction over
5–8.5 years of follow-up. No signiﬁcant changes in
BP were found from baseline to end-point (Table 3)
(39). However, in a post hoc analysis of the CDP
in patients with metabolic syndrome according to
criteria established by the National Cholesterol
Education Program (40), treatment with niacin was
associated with a mild but statistically signiﬁcant
reduction in BP compared with placebo at treat-
ment year 1. Compared with baseline, SBP declined
by a mean of 2.2 mmHg (vs. +0.8 mmHg with
placebo; p < 0.0001), and DBP declined by
2.9 mmHg (vs. )0.9 mmHg with placebo;
p < 0.0001) (12).
By categorical analysis of the original CDP data,
signiﬁcantly lower proportions of patients rando-
mised to niacin (vs. placebo) had at least one ele-
vated SBP or DBP reading during 5 years of
treatment (excluding patients with abnormal values
at baseline). A total of 26.8% of the niacin group
had SBP ‡ 160 mmHg compared with 30.6% of the
placebo group (z = )2.23). A total of 8.7% of the
niacin group had SBP ‡ 180 mmHg compared with
10.7% of the placebo group (z = )1.77). Corres-
ponding data for DBP were 53.1% of niacin patients
having DBP ‡ 90 mmHg compared with 60.4% for
placebo (z = )3.44) and 6.3% of niacin patients
having DBP ‡ 110 mmHg compared with 9.2% for
Table 3 (continued)
Study Patients
Duration;
outcome measure
Daily dose of
regimen (n with
available BL and
EP data for BP)
Baseline
mean BP, mmHg
End-point
(or on-trial)
mean BP, mmHg Comparison
Stockholm
Ischaemic Heart
Study, Carlson
and
Rosenhamer
(13)
n = 555 consecutive
MI survivors ages
< 70 years
Up to 5 years; total
mortality, CV-speciﬁc
mortality; non-fatal
CV events
Colestipol = 2 g +
niacin = 3 g
(n = 279 BL;
n = 238, 1 year;
n = 211, 2 years;
n = 183, 3 years)
SBP = 133
DBP = 82
1 year: SBP = 148
DBP = 86
2 years: SBP = 149
DBP = 88
3 years: SBP = 148
DBP = 87
p = ns for each
comparison vs. control
at each time point
Control (n = 276 BL;
n = 245, 1 year;
n = 211, 2 years;
n = 185, 3 years)
SBP = 128
DBP = 79
1 year: SBP = 146
DBP = 86
2 years: SBP = 146
DBP = 87
3 years: SBP = 146
DBP = 85
*z > 2.58 or < )2.58 was considered to be statistically signiﬁcant (at two-sided a = 0.01). AFREGS, Armed Forces Regression Study; BL, baseline; BP, blood pres-
sure; CABG, coronary artery bypass surgery; CHD, coronary heart disease; CLAS, Cholesterol Lowering Atherosclerosis Study; CME, cholestyramine; CV, cardiovascu-
lar; DBP, diastolic blood pressure; EP, end-point; HATS, HDL-Atherosclerosis Treatment Study; HDL-C, high-density lipoprotein cholesterol; MI, myocardial infarction;
ns, not signiﬁcant; SBP, systolic blood pressure; TIA, transient ischemic attack.
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group difference (39).
More recent data of large numbers of niacin-trea-
ted patients also support these ﬁndings. Laropiprant
is being investigated as an inhibitor of the prosta-
glandin D2 (PGD2) receptor, which mediates ﬂushing
(41,42). A short-term titration study of 412 patients
administered extended-release niacin 1–2 g⁄day with
laropiprant for up to 8 weeks showed no signiﬁcant
change in BP from baseline (43). However, in a
longer (24-week) and much larger (n = 1613) study,
patients with dyslipidaemia were randomised to one
of three treatment arms: extended-release niacin 1 g,
extended-release niacin 1 g plus laropiprant 20 mg,
or placebo once daily for 4 weeks. Afterwards, the
doses were doubled for another 20 weeks of treat-
ment (3). In a post hoc analysis of this study, reduc-
tions in BP were signiﬁcant in patients receiving
either extended-release niacin or extended-release
niacin⁄laropiprant compared with placebo at both 4
and 24 weeks, and this effect seemed to be dose
dependent (Figure 1) (3). Laropiprant neither abol-
ished nor attenuated the BP-lowering effects of nia-
cin, suggesting that the effects of chronic niacin in
lowering BP is not because of PGD2-mediated ﬂush-
ing.
Discussion
Clinical trials suggest that infusion of niacin may
acutely lower BP in some individuals. Clinical prac-
tice experience suggests that, rarely, oral administra-
tion may also acutely lower BP, especially when
severe niacin-induced ﬂushing occurs. This acute BP
lowering is described in the package insert of the
currently marketed prescription niacin. It is tempting
to speculate that the acute BP effect of acute niacin
administration is linked to the vasodilatation induced
by niacin. From an efﬁcacy standpoint, niacin acti-
vates the G protein-coupled GPR109A receptors on
cells such as adipocytes, which may favourably inﬂu-
ence lipid metabolism. From an adverse experience
standpoint, these same receptors are also found on
epidermal Langerhans cells in the skin (44), which
generate prostaglandins such as PGD2, which in turn,
stimulates PGD2 type 1 (PD1) receptors on vascular
smooth-muscle cells in dermal arterioles, causing
vasodilatation and ﬂushing. GPR109A activation on
Langerhans cells may also generate PGE2 and possi-
bly other mediators that could conceivably inﬂuence
vascular tone and thus may also contribute to lower
BP. Additionally, niacin could conceivably activate
its receptor on other cell types (including other com-
ponents of the cardiovascular system) that might
lead to haemodynamic changes. Finally, niacin could
have other ‘off-target’ effects (not mediated by
GPR109A) that could have acute BP effects.
The potential chronic BP-lowering effects of niacin
are best supported by longer niacin trials involving
larger numbers of patients. The recent clinical trial
experience with laropiprant suggests that any chronic
BP-lowering effects of niacin are not likely mediated
by DP1 receptors or cutaneous vasodilatation. Thus,
the mechanism that might account for chronic low-
ering of BP by niacin is unknown. One intriguing
possibility is that niacin may lower BP at least in
part, because of favourable lipid-altering effects that
might improve endothelial function. One of the
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Figure 1 Effects of extended-release niacin alone or with laropiprant on blood pressure. Reductions in blood pressure were signiﬁcant in patients
receiving either extended-release niacin (ERN) or extended-release niacin⁄laropiprant (ERN⁄LRPT) compared with placebo at both 4 and 24 weeks (3)
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HDL-C levels. HDL particles have many important
lipid, antioxidant and anti-inﬂammatory functions
that favourably affect the vasculature. HDL-C levels
directly correlate with measures of endothelial func-
tion (45). The apolipoprotein B⁄A-1 ratio is inversely
associated with endothelium-dependent vasodilation
(46). HDL activates endothelial nitric oxide synthase
and generates nitric oxide in endothelial cells in vitro
and in vivo (47), and niacin’s HDL-mediated endo-
thelial nitric oxide production may contribute to
modest chronic BP lowering with long-term therapy.
It is especially interesting to note that, when niacin
has been reported to chronically lower BP, the effects
have generally been progressive and gradual, occur-
ring over many months or years. These ﬁndings cor-
relate to one of the more interesting therapeutic
effects of niacin, which is that HDL-C levels may
continue to rise, even after many months, and up to
a year, after treatment onset (48).
It is somewhat surprising that chronic BP lower-
ing observed with long-term niacin administration,
as indicated in studies such as the CDP, has not
been more completely evaluated and better charac-
terised, especially given that (i) niacin has been in
clinical use for decades; (ii) acute niacin infusion
sometimes acutely lowers BP; (iii) multiple clinical
trials support the conclusion that niacin favourably
affects atherosclerosis; and (iv) elevated BP is a well-
established cardiovascular risk factor. As such, the
conclusion of this review is limited by the lack of
formal BP evaluations in most niacin clinical trials,
and a lack of consistent reporting of niacin’s effects
upon normotensive compared with hypertensive
subjects. It would be of interest to determine
whether any demographic or clinical characteristics
exist that could help to predict which patients are
more likely to experience the haemodynamic effects
of niacin, when administered alone or in concert
with statins and⁄or laropiprant to control ﬂushing.
Such ongoing trials that might best answer these
questions include Atherothrombosis in Metabolic
Syndrome with Low HDL⁄High Triglycerides and
Impact on Global Health Outcomes and Heart Pro-
tection Study 2–Treatment of HDL to Reduce the
Incidence of Vascular Events. But currently, no
long-term clinical trial has yet been conducted spe-
ciﬁcally evaluating niacin’s chronic BP effect as a
primary end-point, and controlled clinical trials are
needed with ambulatory BP monitoring and other
such measures that are more typical for assessing
the efﬁcacy of antihypertensive agents. Through such
studies and others, a better determination can be
made regarding niacin’s effect upon BP, and
whether it is possible that the long-term administra-
tion of niacin may contribute to its overall cardio-
protective beneﬁts.
Conclusions
Small clinical trials of acute niacin administration
have shown signiﬁcant BP-lowering effects of niacin
in patients with hypertension but not necessarily in
normotensive individuals. Acute lowering of BP is
occasionally found with niacin’s clinical use, and is
described in the package insert of prescription niacin.
Regarding chronic BP effects, most large, prospective,
randomised clinical trials involving niacin and nia-
cin-containing regimens (e.g. the CDP) showed
either no clear signiﬁcant effects of niacin or slightly
lower mean BP among some niacin treatment groups
compared with placebo. Recent clinical trials involv-
ing co-administration of the PGD2 receptor antago-
nist laropiprant suggest that niacin may indeed have
dose-dependent chronic BP-lowering effects, which
are unlikely to be due to DP1 receptor activation
leading to vasodilatation. Future analysis of ongoing
niacin clinical trials, and more formalised future clin-
ical trials speciﬁcally designed to better assess niacin’s
BP effects, may help researchers and clinicians to
better appreciate the extent of niacin’s effects on the
important cardiovascular risk factor of hypertension.
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